Published in Clin Microbiol Rev on January 01, 2011
Behavioral, virologic, and immunologic factors associated with acquisition and severity of primary Epstein-Barr virus infection in university students. J Infect Dis (2012) 2.33
Virus identification in unknown tropical febrile illness cases using deep sequencing. PLoS Negl Trop Dis (2012) 1.52
Epstein-Barr and other herpesvirus infections in patients with early onset type 1 diabetes treated with daclizumab and mycophenolate mofetil. Clin Infect Dis (2012) 1.47
Current views and advances on Paediatric Virology: An update for paediatric trainees. Exp Ther Med (2015) 1.44
Primary Epstein-Barr virus infection does not erode preexisting CD8⁺ T cell memory in humans. J Exp Med (2012) 1.20
Herpesviruses: latency and reactivation - viral strategies and host response. J Oral Microbiol (2013) 1.14
Cutting edge: NKG2C(hi)CD57+ NK cells respond specifically to acute infection with cytomegalovirus and not Epstein-Barr virus. J Immunol (2014) 1.08
Infectious mononucleosis. Clin Transl Immunology (2015) 0.99
Roles of the PI3K/Akt pathway in Epstein-Barr virus-induced cancers and therapeutic implications. World J Virol (2012) 0.98
Acute retinal necrosis associated with Epstein-Barr virus: immunohistopathologic confirmation. JAMA Ophthalmol (2014) 0.97
Clinical outcome of Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly in the rituximab era. Cancer Sci (2014) 0.90
Observed positive correlation between Epstein-Barr virus infection and focal choroidal excavation. Int Ophthalmol (2013) 0.88
Approved Antiviral Drugs over the Past 50 Years. Clin Microbiol Rev (2016) 0.88
Implication of human herpesviruses in oncogenesis through immune evasion and supression. Infect Agent Cancer (2014) 0.87
The Incubation Period of Primary Epstein-Barr Virus Infection: Viral Dynamics and Immunologic Events. PLoS Pathog (2015) 0.86
Primary EBV infection induces an expression profile distinct from other viruses but similar to hemophagocytic syndromes. PLoS One (2014) 0.85
Effect of high dose vitamin C on Epstein-Barr viral infection. Med Sci Monit (2014) 0.85
The prognostic impact of RAP2A expression in patients with early and locoregionally advanced nasopharyngeal carcinoma in an endemic area. Am J Transl Res (2015) 0.83
Clinical and laboratory characteristics of infectious mononucleosis by Epstein-Barr virus in Mexican children. BMC Res Notes (2012) 0.81
Acute Retinal Necrosis Associated with Epstein-Barr Virus in a Patient Undergoing Immunosuppressive Therapy. Case Rep Ophthalmol (2016) 0.81
The expression of renal Epstein-Barr virus markers in patients with lupus nephritis. Exp Ther Med (2014) 0.81
Performance of two commercially available automated immunoassays for the determination of Epstein-Barr virus serological status. Clin Vaccine Immunol (2012) 0.79
Antiviral antibody profiling by high-density protein arrays. Proteomics (2015) 0.78
Epstein-Barr virus dynamics in asymptomatic immunocompetent adults: an intensive 6-month study. Clin Transl Immunology (2016) 0.78
Evaluation of the Architect Epstein-Barr Virus (EBV) viral capsid antigen (VCA) IgG, VCA IgM, and EBV nuclear antigen 1 IgG chemiluminescent immunoassays for detection of EBV antibodies and categorization of EBV infection status using immunofluorescence assays as the reference method. Clin Vaccine Immunol (2014) 0.78
Interaction of human tumor viruses with host cell surface receptors and cell entry. Viruses (2015) 0.78
A large-scale seroprevalence of Epstein-Barr virus in Taiwan. PLoS One (2015) 0.78
Epstein-Barr Virus: Diseases Linked to Infection and Transformation. Front Microbiol (2016) 0.78
Murine Gammaherpesvirus 68 Pathogenesis Is Independent of Caspase-1 and Caspase-11 in Mice and Impairs Interleukin-1β Production upon Extrinsic Stimulation in Culture. J Virol (2015) 0.77
The impact of serological features in Chinese children with primary or past Epstein-Barr virus infections. Virol J (2013) 0.77
Infectious Mononucleosis. Curr Top Microbiol Immunol (2015) 0.77
The levels of liver enzymes and atypical lymphocytes are higher in youth patients with infectious mononucleosis than in preschool children. Clin Mol Hepatol (2013) 0.77
Epstein-Barr virus replicating in epithelial cells. Proc Natl Acad Sci U S A (2014) 0.76
Human-derived IgG level as an indicator for EBV-associated lymphoma model in Hu-PBL/SCID chimeras. Virol J (2011) 0.76
Salivary and serum IL-10, TNF-α, TGF-β, VEGF levels in oropharyngeal squamous cell carcinoma and correlation with HPV and EBV infections. Infect Agent Cancer (2016) 0.76
Epstein-Barr Virus BZLF1-Mediated Downregulation of Proinflammatory Factors Is Essential for Optimal Lytic Viral Replication. J Virol (2015) 0.76
Epstein-Barr Virus-Induced Mononucleosis as an Imitator of Severe Preeclampsia. AJP Rep (2017) 0.75
Chest pain in a young patient: an unusual complication of Epstein-Barr virus. BMJ Case Rep (2014) 0.75
Acute systemic viral infection masquerading as an infiltrating lymphoma in an elderly patient: a case report and review of the literature. Case Rep Med (2013) 0.75
Targeting the Ca(2+) Sensor STIM1 by Exosomal Transfer of Ebv-miR-BART13-3p is Associated with Sjögren's Syndrome. EBioMedicine (2016) 0.75
Prospective studies of infectious mononucleosis in university students. Clin Transl Immunology (2016) 0.75
Frequency of Epstein - Barr Virus in Patients Presenting with Acute Febrile Illness in Kenya. PLoS One (2016) 0.75
Epstein-Barr Virus-Positive Posttransplant Lymphoproliferative Disease After Solid Organ Transplantation: Pathogenesis, Clinical Manifestations, Diagnosis, and Management. Transplant Direct (2015) 0.75
Herpesvirus Infections and Risk of Frailty and Mortality in Older Women: Women's Health and Aging Studies. J Am Geriatr Soc (2016) 0.75
Higher Frequency of CD4+CXCR5+ICOS+PD1+ T Follicular Helper Cells in Patients With Infectious Mononucleosis. Medicine (Baltimore) (2015) 0.75
Visual detection and evaluation of latent and lytic gene expression during Epstein-Barr virus infection using one-step reverse transcription loop-mediated isothermal amplification. Int J Mol Sci (2013) 0.75
Epstein- Barr Virus: Clinical and Epidemiological Revisits and Genetic Basis of Oncogenesis. Open Virol J (2015) 0.75
Evolution of EBV seroprevalence and primary infection age in a French hospital and a city laboratory network, 2000-2016. PLoS One (2017) 0.75
The Role of Latently Infected B Cells in CNS Autoimmunity. Front Immunol (2015) 0.75
Acute Epstein - Barr virus hepatitis without mononucleosis syndrome: a case report. Gastroenterol Hepatol Bed Bench (2017) 0.75
Causal role of infectious agents in cancer: An overview. Caspian J Intern Med (2017) 0.75
A Rare Case of Three Distinct Epstein-Barr Virus Associated Lymphoproliferative Disorders Over Sixteen Years of Human Immunodeficiency Virus Infection. Hematol Rep (2017) 0.75
VIRUS PARTICLES IN CULTURED LYMPHOBLASTS FROM BURKITT'S LYMPHOMA. Lancet (1964) 14.21
Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine. Proc Natl Acad Sci U S A (1977) 11.20
Epstein-Barr virus: 40 years on. Nat Rev Cancer (2004) 9.70
Relation of Burkitt's tumor-associated herpes-ytpe virus to infectious mononucleosis. Proc Natl Acad Sci U S A (1968) 8.67
Homology of cytokine synthesis inhibitory factor (IL-10) to the Epstein-Barr virus gene BCRFI. Science (1990) 7.18
Persistence of the Epstein-Barr virus and the origins of associated lymphomas. N Engl J Med (2004) 5.61
SAP-controlled T-B cell interactions underlie germinal centre formation. Nature (2008) 5.14
The X-linked lymphoproliferative-disease gene product SAP regulates signals induced through the co-receptor SLAM. Nature (1998) 4.47
EBV persistence in memory B cells in vivo. Immunity (1998) 4.44
Alternate replication in B cells and epithelial cells switches tropism of Epstein-Barr virus. Nat Med (2002) 4.33
Herpesvirus latency confers symbiotic protection from bacterial infection. Nature (2007) 4.27
Meta-analysis: the efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann Intern Med (2005) 4.27
Cellular responses to viral infection in humans: lessons from Epstein-Barr virus. Annu Rev Immunol (2007) 4.14
Interleukin-10: new perspectives on an old cytokine. Immunol Rev (2008) 3.94
Host response to EBV infection in X-linked lymphoproliferative disease results from mutations in an SH2-domain encoding gene. Nat Genet (1998) 3.94
Evolutionary struggles between NK cells and viruses. Nat Rev Immunol (2008) 3.79
Localization of Epstein-Barr virus cytotoxic T cell epitopes using recombinant vaccinia: implications for vaccine development. J Exp Med (1992) 3.75
Regulation of NKT cell development by SAP, the protein defective in XLP. Nat Med (2005) 3.62
Epstein-Barr virus types 1 and 2 differ in their EBNA-3A, EBNA-3B, and EBNA-3C genes. J Virol (1990) 3.54
Influence of the Epstein-Barr virus nuclear antigen EBNA 2 on the growth phenotype of virus-transformed B cells. J Virol (1987) 3.53
Murine gamma-herpesvirus 68 causes severe large-vessel arteritis in mice lacking interferon-gamma responsiveness: a new model for virus-induced vascular disease. Nat Med (1997) 3.40
The transmission of infectious mononucleosis. Am J Med Sci (1955) 3.32
Infectious mononucleosis. N Engl J Med (2010) 3.10
Memory of mice and men: CD8+ T-cell cross-reactivity and heterologous immunity. Immunol Rev (2006) 2.79
T-cell lymphomas containing Epstein-Barr viral DNA in patients with chronic Epstein-Barr virus infections. N Engl J Med (1988) 2.63
Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. Blood (2007) 2.61
Pharmacokinetics of the acyclovir pro-drug valaciclovir after escalating single- and multiple-dose administration to normal volunteers. Clin Pharmacol Ther (1993) 2.52
Inactivating mutations in an SH2 domain-encoding gene in X-linked lymphoproliferative syndrome. Proc Natl Acad Sci U S A (1998) 2.46
An Epstein-Barr virus-specific cytotoxic T cell epitope in EBV nuclear antigen 3 (EBNA 3). J Exp Med (1990) 2.44
Human natural killer cell deficiencies and susceptibility to infection. Microbes Infect (2002) 2.43
Infectious mononucleosis. Am J Med (1952) 2.25
Clinical spectrum of lymphoproliferative disorders in renal transplant recipients and evidence for the role of Epstein-Barr virus. Cancer Res (1981) 2.25
Epstein-Barr virus infection of polarized tongue and nasopharyngeal epithelial cells. Nat Med (2003) 2.21
Human CD8+ T cell responses to EBV EBNA1: HLA class I presentation of the (Gly-Ala)-containing protein requires exogenous processing. Immunity (1997) 2.18
Antiviral immune responses: triggers of or triggered by autoimmunity? Nat Rev Immunol (2009) 2.16
Eradication of Epstein-Barr virus by allogeneic bone marrow transplantation: implications for sites of viral latency. Proc Natl Acad Sci U S A (1988) 2.12
A prospective clinical study of Epstein-Barr virus and host interactions during acute infectious mononucleosis. J Infect Dis (2005) 2.09
Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: a systematic review of randomised controlled trials. Lancet (2005) 2.09
Clinical and virologic characteristics of chronic active Epstein-Barr virus infection. Blood (2001) 2.05
Geographical prevalence of two types of Epstein-Barr virus. Virology (1986) 2.05
Interlaboratory comparison of epstein-barr virus viral load assays. Am J Transplant (2009) 2.04
Prolonged inhibitory effect of 9-(1,3-dihydroxy-2-propoxymethyl)guanine against replication of Epstein-Barr virus. J Virol (1984) 1.88
Prospective studies of a group of Yale University freshmen. I. Occurrence of infectious mononucleosis. J Infect Dis (1971) 1.85
Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease. Proc Natl Acad Sci U S A (1999) 1.82
Fusion of epithelial cells by Epstein-Barr virus proteins is triggered by binding of viral glycoproteins gHgL to integrins alphavbeta6 or alphavbeta8. Proc Natl Acad Sci U S A (2009) 1.79
Epstein-Barr virus and human diseases: recent advances in diagnosis. Clin Microbiol Rev (1988) 1.78
Multicenter comparison of different real-time PCR assays for quantitative detection of Epstein-Barr virus. J Clin Microbiol (2007) 1.77
A phase I trial of epstein-barr virus gp350 vaccine for children with chronic kidney disease awaiting transplantation. Transplantation (2009) 1.77
Routine Epstein-Barr virus diagnostics from the laboratory perspective: still challenging after 35 years. J Clin Microbiol (2004) 1.76
Impaired Epstein-Barr virus-specific CD8+ T-cell function in X-linked lymphoproliferative disease is restricted to SLAM family-positive B-cell targets. Blood (2010) 1.75
The biology and chemistry of Epstein-Barr virus. J Infect Dis (1982) 1.74
Epstein-Barr virus associated B cell lymphoproliferative disorders following bone marrow transplantation. Blood (1988) 1.72
Epstein-Barr virus genome-positive T lymphocytes in a boy with chronic active EBV infection associated with Kawasaki-like disease. Nature (1988) 1.71
Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. ASTS/ASTP EBV-PTLD Task Force and The Mayo Clinic Organized International Consensus Development Meeting. Transplantation (1999) 1.70
Using Epstein-Barr viral load assays to diagnose, monitor, and prevent posttransplant lymphoproliferative disorder. Clin Microbiol Rev (2010) 1.68
Proposed guidelines for diagnosing chronic active Epstein-Barr virus infection. Am J Hematol (2005) 1.65
A cohort study among university students: identification of risk factors for Epstein-Barr virus seroconversion and infectious mononucleosis. Clin Infect Dis (2006) 1.64
A study of risk factors for acquisition of Epstein-Barr virus and its subtypes. J Infect Dis (2007) 1.62
Infectious mononucleosis at the United States Military Academy. A prospective study of a single class over four years. Yale J Biol Med (1974) 1.61
Epstein-Barr virus (EBV)-encoded small RNA is released from EBV-infected cells and activates signaling from Toll-like receptor 3. J Exp Med (2009) 1.60
Reactivation of Epstein-Barr virus from latency. Rev Med Virol (2005) 1.58
Molecular virology of Epstein-Barr virus. Philos Trans R Soc Lond B Biol Sci (2001) 1.54
Clinical and virological characteristics of 15 patients with chronic active Epstein-Barr virus infection treated with hematopoietic stem cell transplantation. Clin Infect Dis (2008) 1.54
Pathogenesis of chronic active Epstein-Barr virus infection: is this an infectious disease, lymphoproliferative disorder, or immunodeficiency? Rev Med Virol (2006) 1.53
Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: analysis of prognostic variables and long-term follow-up of 42 adult patients. Transplantation (2001) 1.53
Mononucleosis and athletic participation: an evidence-based subject review. Clin J Sport Med (2008) 1.48
Epstein-Barr virus infection in ex vivo tonsil epithelial cell cultures of asymptomatic carriers. J Virol (2004) 1.48
Molecular diagnosis of Epstein-Barr virus-related diseases. J Mol Diagn (2001) 1.47
Latent and lytic Epstein-Barr virus replication strategies. Rev Med Virol (2004) 1.45
Toward standardization of Epstein-Barr virus DNA load monitoring: unfractionated whole blood as preferred clinical specimen. J Clin Microbiol (2001) 1.45
Post-transplant lymphoproliferative disorder: a review. Bone Marrow Transplant (2003) 1.43
Activated lymphocytes during acute Epstein-Barr virus infection. J Immunol (1987) 1.42
Inhibition of Epstein-Barr virus replication by a benzimidazole L-riboside: novel antiviral mechanism of 5, 6-dichloro-2-(isopropylamino)-1-beta-L-ribofuranosyl-1H-benzimidazole. J Virol (1999) 1.39
Acute complications of Epstein-Barr virus infectious mononucleosis. Curr Opin Pediatr (2000) 1.38
Acute infection with Epstein-Barr virus targets and overwhelms the peripheral memory B-cell compartment with resting, latently infected cells. J Virol (2004) 1.36
On the dynamics of acute EBV infection and the pathogenesis of infectious mononucleosis. Blood (2007) 1.36
Antiviral drugs. N Engl J Med (1999) 1.36
Seroepidemiologic study of Epstein-Barr virus infections in a rural community. J Infect Dis (1975) 1.35
In vivo kinetics of human natural killer cells: the effects of ageing and acute and chronic viral infection. Immunology (2007) 1.35
Outcome of treatment of Epstein-Barr virus-related post-transplant lymphoproliferative disorder in hematopoietic stem cell recipients: a comprehensive review of reported cases. Transpl Infect Dis (2009) 1.35
X-linked lymphoproliferative disease: a progressive immunodeficiency. Annu Rev Immunol (2001) 1.33
Treatment of PTLD with rituximab or chemotherapy. Am J Transplant (2006) 1.33
Patients at risk for development of posttransplant lymphoproliferative disorder: plasma versus peripheral blood mononuclear cells as material for quantification of Epstein-Barr viral load by using real-time quantitative polymerase chain reaction. Transplantation (2001) 1.32
Manipulation of the toll-like receptor 7 signaling pathway by Epstein-Barr virus. J Virol (2007) 1.31
Splenic rupture in infectious mononucleosis. Ann Intern Med (1957) 1.31
The immune response to primary EBV infection: a role for natural killer cells. Br J Haematol (2005) 1.30
CD3-negative lymphoproliferative disease of granular lymphocytes containing Epstein-Barr viral DNA. J Clin Invest (1989) 1.29
Phase I trial of a CD8+ T-cell peptide epitope-based vaccine for infectious mononucleosis. J Virol (2007) 1.28
The EB virus. Annu Rev Microbiol (1973) 1.28
Measurement of Epstein-Barr virus DNA loads in whole blood and plasma by TaqMan PCR and in peripheral blood lymphocytes by competitive PCR. J Clin Microbiol (2003) 1.27
The EBV-encoded dUTPase activates NF-kappa B through the TLR2 and MyD88-dependent signaling pathway. J Immunol (2009) 1.25
First EBV vaccine trial in humans using recombinant vaccinia virus expressing the major membrane antigen. Dev Biol Stand (1995) 1.25
High levels of Epstein-Barr virus DNA in blood of solid-organ transplant recipients and their value in predicting posttransplant lymphoproliferative disorders. J Clin Microbiol (2000) 1.24
Positive and negative selection of T cells. Annu Rev Immunol (2002) 8.32
T cell receptor signal strength in Treg and iNKT cell development demonstrated by a novel fluorescent reporter mouse. J Exp Med (2011) 4.71
Kruppel-like factor 2 regulates thymocyte and T-cell migration. Nature (2006) 4.51
Identification of a novel population of Langerin+ dendritic cells. J Exp Med (2007) 4.13
KLF2 transcription-factor deficiency in T cells results in unrestrained cytokine production and upregulation of bystander chemokine receptors. Immunity (2009) 2.90
Thymic emigration revisited. J Exp Med (2007) 2.60
T cells expressing the transcription factor PLZF regulate the development of memory-like CD8+ T cells. Nat Immunol (2010) 2.49
Steady-state production of IL-4 modulates immunity in mouse strains and is determined by lineage diversity of iNKT cells. Nat Immunol (2013) 2.33
Behavioral, virologic, and immunologic factors associated with acquisition and severity of primary Epstein-Barr virus infection in university students. J Infect Dis (2012) 2.33
Transcriptional downregulation of S1pr1 is required for the establishment of resident memory CD8+ T cells. Nat Immunol (2013) 2.23
Selection of self-reactive T cells in the thymus. Annu Rev Immunol (2011) 1.98
Clonal deletion of thymocytes can occur in the cortex with no involvement of the medulla. J Exp Med (2008) 1.86
The timing of TCR alpha expression critically influences T cell development and selection. J Exp Med (2005) 1.85
Sweet 'n' sour: the impact of differential glycosylation on T cell responses. Nat Immunol (2002) 1.65
Distinct temporal patterns of T cell receptor signaling during positive versus negative selection in situ. Sci Signal (2013) 1.63
A requirement for sustained ERK signaling during thymocyte positive selection in vivo. Proc Natl Acad Sci U S A (2005) 1.60
Alternative memory in the CD8 T cell lineage. Trends Immunol (2011) 1.60
Langerhans cells activate naive self-antigen-specific CD8 T cells in the steady state. Immunity (2004) 1.58
Langerin expressing cells promote skin immune responses under defined conditions. J Immunol (2008) 1.54
Murine thymic selection quantified using a unique method to capture deleted T cells. Proc Natl Acad Sci U S A (2013) 1.52
The autoimmunity-associated gene PTPN22 potentiates toll-like receptor-driven, type 1 interferon-dependent immunity. Immunity (2013) 1.49
Basal immunoglobulin signaling actively maintains developmental stage in immature B cells. PLoS Biol (2005) 1.47
Acute ablation of Langerhans cells enhances skin immune responses. J Immunol (2010) 1.47
Rare, structurally homologous self-peptides promote thymocyte positive selection. Immunity (2002) 1.41
Transcriptional analysis of clonal deletion in vivo. J Immunol (2007) 1.39
The fourth way? Harnessing aggressive tendencies in the thymus. J Immunol (2004) 1.31
Thymic emigration: when and how T cells leave home. J Immunol (2008) 1.31
T-cell tolerance: central and peripheral. Cold Spring Harb Perspect Biol (2012) 1.28
Primary Epstein-Barr virus infection does not erode preexisting CD8⁺ T cell memory in humans. J Exp Med (2012) 1.20
Kruppel-like factor 2 is required for trafficking but not quiescence in postactivated T cells. J Immunol (2010) 1.19
The regulated expression of a diverse set of genes during thymocyte positive selection in vivo. J Immunol (2004) 1.15
A spontaneous CD8 T cell-dependent autoimmune disease to an antigen expressed under the human keratin 14 promoter. J Immunol (2002) 1.12
Langerhans cells are not required for the CD8 T cell response to epidermal self-antigens. J Immunol (2009) 1.12
Krüppel-like factor 2 (KLF2) regulates B-cell reactivity, subset differentiation, and trafficking molecule expression. Proc Natl Acad Sci U S A (2010) 1.12
Positive selection optimizes the number and function of MHCII-restricted CD4+ T cell clones in the naive polyclonal repertoire. Proc Natl Acad Sci U S A (2009) 1.09
Cutting edge: NKG2C(hi)CD57+ NK cells respond specifically to acute infection with cytomegalovirus and not Epstein-Barr virus. J Immunol (2014) 1.08
Virtual memory CD8 T cells display unique functional properties. Proc Natl Acad Sci U S A (2013) 1.04
Krüppel-like factor 2 regulates trafficking and homeostasis of gammadelta T cells. J Immunol (2010) 1.02
T-cell receptor affinity in thymic development. Immunology (2012) 0.99
An isocratic liquid chromatography method for determining HIV non-nucleoside reverse transcriptase inhibitor and protease inhibitor concentrations in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci (2006) 0.99
Thymoproteasome subunit-β5T generates peptide-MHC complexes specialized for positive selection. Proc Natl Acad Sci U S A (2013) 0.98
EBV-positive mucocutaneous ulcer in organ transplant recipients: a localized indolent posttransplant lymphoproliferative disorder. Am J Surg Pathol (2014) 0.98
Antigen receptor selection by editing or downregulation of V(D)J recombination. Curr Opin Immunol (2003) 0.97
Central tolerance: what have we learned from mice? Semin Immunopathol (2008) 0.97
Krüppel-like factors in lymphocyte biology. J Immunol (2012) 0.97
CD53, a thymocyte selection marker whose induction requires a lower affinity TCR-MHC interaction than CD69, but is up-regulated with slower kinetics. Int Immunol (2002) 0.96
Thymocyte sensitivity and supramolecular activation cluster formation are developmentally regulated: a partial role for sialylation. J Immunol (2003) 0.95
Epstein-Barr virus vaccine for the prevention of infectious mononucleosis--and what else? J Infect Dis (2007) 0.95
A randomized crossover study to determine bioequivalence of generic and brand name nevirapine, zidovudine, and lamivudine in HIV-negative women in India. J Acquir Immune Defic Syndr (2006) 0.92
Quantitative Epstein-Barr virus shedding and its correlation with the risk of post-transplant lymphoproliferative disorder. Clin Transplant (2012) 0.92
Conditioning of Langerhans cells induced by a primary CD8 T cell response to self-antigen in vivo. J Immunol (2006) 0.91
Postselection thymocyte maturation and emigration are independent of IL-7 and ERK5. J Immunol (2010) 0.91
Epidermal Langerhans cells are not required for UV-induced immunosuppression. J Immunol (2009) 0.91
Central tolerance to self-antigen expressed by cortical epithelial cells. J Immunol (2004) 0.89
Development of promyelocytic leukemia zinc finger-expressing innate CD4 T cells requires stronger T-cell receptor signals than conventional CD4 T cells. Proc Natl Acad Sci U S A (2012) 0.88
Simultaneous determination of acyclovir, ganciclovir, and (R)-9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine in human plasma using high-performance liquid chromatography. Biomed Chromatogr (2009) 0.87
Predictive value of HIV-1 viral load on risk for opportunistic infection. J Acquir Immune Defic Syndr (2002) 0.86
Cholera toxin activates nonconventional adjuvant pathways that induce protective CD8 T-cell responses after epicutaneous vaccination. Proc Natl Acad Sci U S A (2012) 0.85
The virologic and immunologic effects of cyclosporine as an adjunct to antiretroviral therapy in patients treated during acute and early HIV-1 infection. J Infect Dis (2010) 0.85
Alterations in the C-terminal region of the HIV-1 accessory gene vpr do not confer clinical advantage to subjects receiving nucleoside antiretroviral therapy. J Infect Dis (2004) 0.84
Thymic emigration: sphingosine-1-phosphate receptor-1-dependent models and beyond. Eur J Immunol (2009) 0.83
Primary Epstein-Barr virus infection: impact of age at acquisition, coinfection, and viral load. J Infect Dis (2013) 0.83
T-cell migration: Kruppeled T cells move again. Immunol Cell Biol (2008) 0.81
The impact of donor viral replication at transplant on recipient infections posttransplant: a prospective study. Transplantation (2015) 0.80
Valacyclovir pharmacokinetics and exploratory pharmacodynamics in young adults with Epstein-Barr virus infectious mononucleosis. J Clin Pharmacol (2009) 0.80
Immunodeficiency: when T cells are stuck at home. Nat Immunol (2008) 0.80
Valganciclovir administration to kidney donors to reduce the burden of cytomegalovirus and Epstein-Barr virus transmission during transplantation. Transplantation (2015) 0.80
Coinfection alters the playing field: herpesviruses induce acyclovir to inhibit HIV. Cell Host Microbe (2008) 0.78
The central tolerance response to male antigen in normal mice is deletion and not receptor editing. J Immunol (2003) 0.78
Death diverted, but to what? Nat Immunol (2012) 0.77
Pillars article: T cell receptor antagonist peptides induce positive selection. Cell. 1994. 76: 17-27. J Immunol (2012) 0.77
The pharmacokinetics of valganciclovir prophylaxis in pediatric solid organ transplant patients at risk for Epstein-Barr virus disease. Clin Pharmacol (2009) 0.75
Population pharmacokinetics of valganciclovir prophylaxis in paediatric and adult solid organ transplant recipients. Br J Clin Pharmacol (2014) 0.75
Cytomegalovirus retinitis in persons with AIDS. Postgrad Med (1995) 0.75
Intermittent administration of high-dose stavudine to nucleoside-experienced individuals infected with HIV-1. J Acquir Immune Defic Syndr (2003) 0.75
Detection of antiretroviral resistance in HIV-1. Clin Lab Med (2003) 0.75
Lymphocyte mitochondrial biomarkers in asymptomatic HIV-1-infected individuals treated with nucleoside reverse transcriptase inhibitors. AIDS (2002) 0.75
Corrigendum: Spontaneous partial loss of the OT-I transgene. Nat Immunol (2017) 0.75
T cell progenitor therapy-facilitated thymopoiesis depends upon thymic input and continued thymic microenvironment interaction. JCI Insight (2017) 0.75